BR112021024117A2 - Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b - Google Patents

Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b

Info

Publication number
BR112021024117A2
BR112021024117A2 BR112021024117A BR112021024117A BR112021024117A2 BR 112021024117 A2 BR112021024117 A2 BR 112021024117A2 BR 112021024117 A BR112021024117 A BR 112021024117A BR 112021024117 A BR112021024117 A BR 112021024117A BR 112021024117 A2 BR112021024117 A2 BR 112021024117A2
Authority
BR
Brazil
Prior art keywords
pyrazines
glun2b receptor
receptor modulators
glun2b
substituted pyrazol
Prior art date
Application number
BR112021024117A
Other languages
English (en)
Inventor
Curt Dvorak
Heather Coate
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021024117A2 publication Critical patent/BR112021024117A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b. a presente invenção refere-se a pirazolo-pirazinas substituídas como ligantes do receptor glun2b. estes compostos podem ser usados na modulação do receptor de glun2b e em composições farmacêuticas e métodos para o tratamento de estados doentios, distúrbios e condições mediadas pela atividade do receptor de glun2b.
BR112021024117A 2019-06-14 2020-06-12 Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b BR112021024117A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861681P 2019-06-14 2019-06-14
PCT/EP2020/066405 WO2020249802A1 (en) 2019-06-14 2020-06-12 Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
BR112021024117A2 true BR112021024117A2 (pt) 2022-03-22

Family

ID=71111400

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024117A BR112021024117A2 (pt) 2019-06-14 2020-06-12 Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b

Country Status (10)

Country Link
US (2) US20220315590A1 (pt)
EP (1) EP3983413A1 (pt)
JP (1) JP2022536773A (pt)
KR (1) KR20220024403A (pt)
CN (1) CN114008052A (pt)
AU (1) AU2020292994A1 (pt)
BR (1) BR112021024117A2 (pt)
CA (1) CA3143105A1 (pt)
MX (1) MX2021015500A (pt)
WO (1) WO2020249802A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CA3143105A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
WO2020249785A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
DE69730980T2 (de) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
WO2003082868A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
BRPI0507501A (pt) 2004-02-18 2007-06-26 Astrazeneca Ab composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
AU2005286593A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
EA201070323A1 (ru) 2007-08-30 2010-10-29 Такеда Фармасьютикал Компани Лимитед Замещенное производное пиразола
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
EP2254580A1 (en) 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2308877B1 (en) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
EP2408753A4 (en) 2009-03-20 2012-11-07 Univ Brandeis COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
EP2570415B1 (en) * 2011-09-19 2015-08-26 Sanofi N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals
WO2013060029A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Allosteric modulators of metabotropic glutamate receptors
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
CA2903293C (en) 2013-03-15 2020-10-13 Plexxikon Inc. Heterocyclic compounds and uses thereof
HUE049469T2 (hu) 2013-06-21 2020-09-28 Zenith Epigenetics Ltd Új biciklusos bromodomén inhibitorok
KR20160036053A (ko) 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
US20170313719A1 (en) 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
HUE047460T2 (hu) 2015-07-09 2020-04-28 Janssen Pharmaceutica Nv Szubsztituált 4-azaindolok és ezek alkalmazása mint GLUN2B receptor modulátorok
AU2017217542B2 (en) 2016-02-10 2021-06-03 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) * 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
KR20200020781A (ko) 2017-06-14 2020-02-26 트레베나, 인코포레이티드. S1p1 활성을 조정하기 위한 화합물 및 그를 사용하는 방법
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
WO2020249785A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
CA3143105A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators

Also Published As

Publication number Publication date
US11214563B2 (en) 2022-01-04
KR20220024403A (ko) 2022-03-03
CA3143105A1 (en) 2020-12-17
WO2020249802A1 (en) 2020-12-17
AU2020292994A1 (en) 2022-01-06
JP2022536773A (ja) 2022-08-18
US20220315590A1 (en) 2022-10-06
US20200392113A1 (en) 2020-12-17
EP3983413A1 (en) 2022-04-20
CN114008052A (zh) 2022-02-01
MX2021015500A (es) 2022-02-10

Similar Documents

Publication Publication Date Title
BR112021024117A2 (pt) Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b
BR112021025141A2 (pt) Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
BR112019006691A2 (pt) 1h-imidazo[4,5-b]piridin-2(3h)-onas substituídas e seu uso como moduladores do receptor de glun2b
BR112021024856A2 (pt) Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b
BR112021025136A2 (pt) Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b
BR112018000468A2 (pt) 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112013004766A2 (pt) 2-amino-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
BR112018016329A2 (pt) 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
BR112016024472A8 (pt) composto, medicamento, e, uso de um composto
CY1117543T1 (el) Αναστολεις βητα-σεκρετασης
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112021025132A2 (pt) Carbamatos de piridina e seu uso como moduladores do receptor glun2b
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
BR112014011333A2 (pt) derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares
BR112021023562A2 (pt) Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b
TN2015000032A1 (en) Inhibitors of beta-secretase
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
EA201891710A1 (ru) Терапевтические соединения
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112016021471A8 (pt) derivados de ácido acético azaindol e seu uso como moduladores de receptor d2 de prosrtglandina
ECSP18041731A (es) Derivados Novedosos de Diamino Piridina
BR112016021443A8 (pt) Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2
BR112022019423A2 (pt) Moduladores de hemoglobina